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Human artificial chromosomes (ACs) are non-integrating 
vectors that may be useful for gene therapy. They assem-
ble in cultured cells following transfection of human 
centromeric α-satellite DNA and segregate efficiently 
alongside the host genome. In the present study, a 33 
kilobase (kb) Factor IX (FIX) gene was incorporated into 
mitotically stable ACs in human HT1080 lung derived 
cells using co-transfection of a bacterial artificial chromo-
some (BAC) harboring synthetic α-satellite DNA and a 
P1 artificial chromosome(PAC) that spans the FIX locus. 
ACs were detected in ≥90% of chromosome spreads in 
8 of 19 lines expanded from drug resistant colonies. FIX 
transgene copy number on ACs was determined by input 
DNA transfection ratios. Furthermore, a low level of FIX 
transcription was detected from ACs with multiple trans-
genes but not from those incorporating a single trans-
gene, suggesting that reducing transgene number may 
limit misexpression. Their potential to segregate cross 
species was measured by transferring ACs into mouse and 
hamster cell lines using microcell-mediated chromosome 
transfer. Lines were obtained where ACs segregated effi-
ciently. The stable segregation of ACs in rodent cells sug-
gests that it should be possible to develop animal models 
to test the capacity of ACs to rescue FIX deficiency.
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INTRODUCTION
Current gene therapy approaches favor the use of viral vectors 
due to their capacity to deliver genes into a large population 
of target cells.1 However, advances in stem cell technology will 
permit genetic modification and ex vivo expansion of engraft-
able stem or progenitor cells, opening the way for alternative 
vector systems. Despite some notable successes with viral vec-
tors, problems have been encountered with immunogenicity, 
activation of oncogenes and failure to provide sustained trans-
gene expression. A novel vector system that may overcome some 
of these problems is the human artificial chromosome (AC). 
Human ACs offer several advantages. (i) They can accommodate 
megabases (Mbs) of DNA including entire genomic loci with 
associated regulatory elements, thus maintaining an appropri-
ate response to all regulatory inputs and promoting long-term 
transgene expression. (ii) They are non-integrating, thus pre-
venting insertional mutagenesis. (iii) They should not elicit an 
immune response.
Human ACs form de novo following introduction of cen-
tromeric α-satellite DNA into cultured cells using transfection, 
invasive bacteria or transduction (reviewed in refs. 2,3). ACs 
are 1–10 Mb in size, comprising multimers of the input DNA 
and are maintained alongside the host chromosomes, exploit-
ing the host cell’s natural replication and segregation machin-
ery. They assemble a functional kinetochore, the proteinaceous 
structure that attaches to the mitotic spindle at cell division4 and 
exhibit low copy number and high mitotic stability. Recently, 
large transgenes have been assembled into human ACs by two 
strategies. (i) Co-transfection of an α-satellite construct with a sec-
ond construct spanning the gene of interest.5–7 (ii) Transfection or 
transduction of in vitro synthesized constructs incorporating both 
α-satellite DNA and a therapeutic gene.8–12 In all cases, trans-
gene bearing ACs were mitotically stable in human HT1080 
cells and where examined, transgene expression was detected 
in human cells.5,6,9–12 The goals of the present study were to con-
struct human ACs incorporating the Factor IX (FIX) genomic 
locus (FIXACs), and investigate parameters influencing trans-
gene copy number and regulation. The ability of FIXACs to 
segregate cross species was examined as a step towards animal 
model development. We report efficient incorporation of a 
33 kb FIX gene (mutations in which cause hemophilia B) into 
FIXACs using co-transfection of a bacterial artificial chromo-
some (BAC) carrying an 86.4 kb synthetic α-satellite insert and 
a 175 kb P1 artificial chromosome (PAC) spanning the FIX 
locus, into human HT1080 cells. The molar ratio of input DNA 
molecules determined FIX transgene copy number and influ-
enced transgene regulation with important therapeutic impli-
cations. FIXACs were transferred into rodent cultured cells 
demonstrating the capacity of FIXACs to segregate cross spe-
cies and generate an efficient donor for future FIXAC transfer 
to stem/progenitor cells by microcell-mediated chromosome 
transfer. Transfer of FIXACs into stem and progenitor cells will 
permit downstream development of animal models to evaluate 
the potential of FIXACs to rescue FIX deficiency.
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RESULTS
Incorporation of the FIX genomic locus into de novo 
human artificial chromosomes
BAC17 (99 kb) incorporates 86.4 kb of synthetic α-satellite (D17Z1) 
from human chromosome 17 (Figure 1a)13 and is an efficient sub-
strate for de novo human AC formation when introduced as a circle 
into HT1080 cells.14–16 PACFIX (175 kb) has a 158 kb genomic insert 
spanning the 33 kb FIX gene plus 4,077 bp of upstream regulatory 
sequence sufficient to direct liver specific expression of the FIX 
gene.17 In order to generate human ACs incorporating the FIX gene 
(FIXACs), BAC17 and PACFIX were co-transfected into HT1080 
cells using either a 1:1, 2:1, or 20:1 BAC17:PACFIX molar ratio. 
G418R colonies were expanded and examined by fluorescence in 
situ hybridization (FISH). FIXACs formed efficiently and assem-
bled both input DNA molecules. In 8 of 19 (42%) cell lines, FIXACs 
were detected in ≥90% of chromosome spreads within a clonal line 
(Figures 1b and 2a and b). In one additional line, FIXACs formed 
in 50% of spreads (Figure 1b). Control transfections of BAC17 
alone resulted in formation of ACs (BAC17-ACs) in greater than 
50% of chromosome spreads in 5 of 25 (20%) cell lines. This rep-
resents an AC formation rate significantly lower than obtained 
by co-transfection (P < 0.025). The average FIXAC copy number 
of 3.5/cell is similar to BAC17-AC copy number (Table 1).14–16 
While integrated copies of the transfected DNA were observed 
in lines harboring both FIXACs and BAC17-ACs, the integration 
frequency was low in 6 of 9 lines that formed a FIXAC, ranging 
from 0–25% of chromosome spreads (Figure 1b and Table 1). The 
TX9C2.6 cell line is a subclone of TX9C2 that has FIXACs in 100% 
of spreads without detectable integrations (Figure 1b and Table 1). 
Figure 1 Construction of de novo human artificial chromosomes 
(ACs) incorporating a 33 kb Factor IX (FIX) gene (FIXAC). (a) Vectors 
used to construct FIXAC. BAC17 is 99 kilobase (kb) and has an 86.4 kb 
insert comprising 32 identical copies of the 2.7 kb higher order repeat, 
D17Z1, from human chromosome 17. The bacterial artificial chromo-
some (BAC) vector (VJ104)13 has a β-geo gene conferring G418 resis-
tance. PACFIX has a sequenced 158 kb genomic insert spanning the 33 kb 
human FIX gene cloned into the pPAC4 vector. pPAC4 has a Blasticidin S 
(BSR) selectable marker gene. A 37 kb NotI (NotI is present in the vector)/
SfiI (position 37090) fragment encompasses the FIX gene (Figure 3). 
The FIX genomic locus was incorporated into de novo human ACs 
(termed FIXACs) following co-transfection of BAC17 and PACFIX into 
human HT1080 cells. G418R colonies were expanded and analyzed by 
fluorescence in situ hybridization for the presence of FIXAC (Figure 2). 
(b) Human AC formation rates (defined as formation of an AC in 50% 
of spreads). Triangles represent individual cell lines in which FIXACs were 
detected. Squares represent control cell lines where a human AC formed 
following transfection of BAC17 as the sole input DNA (BAC17-ACs). The 
Y axis is the % of chromosome spreads in each cell line which harbored 
a human AC. Numbers in parenthesis indicate the percentage of spreads 
in which AC formation was associated with integration of the transfected 
DNA into a host chromosome. The X axis indicates the molar ratio (1:1, 
2:1, or 20:1) of BAC17:PACFIX used in each of the three co-transfection 
assays, and the number of G418R cell lines where a FIXAC formed in each 
transfection. FIXACs were detected in 9/19 lines. FIXACs did not form 
in the remaining 10 lines. In the control, BAC17 formed BAC17-ACs in 
5/25 cell lines. A 6th cell line formed a BAC17-AC in 20% of spreads 
(data not shown). In the remaining BAC17 control lines, the transfected 
DNA did not form an AC.
Figure 2 Fluorescence in situ hybridization (FISH) analysis and CENP-
A detection on FIXACs. (a, b) FISH analysis of metaphase spreads from 
TX9A2 (a) and TX10B1 (b) hybridized with a D17Z1 probe (red, left 
panel) and PACFIX (green, right panel). FIXACs are indicated by arrow-
heads. Split images of the same metaphase spread are shown in each 
panel in (a) and (b). (a, b) Left panels: D17Z1 hybridized with FIXAC 
and endogenous D17Z1 sequences. (a, b) Right panels: PACFIX hybrid-
ized with FIXACs and the endogenous sequences on the X chromosome 
(arrows). White boxed area is magnified in the inset. Chromosomes 
were counterstained with 4’,6-diamidino-2-phenylindole (blue). (c, d) 
Chromosomes from cell lines TX9A2 (c) and TX10B7 (d) were analyzed 
by indirect immunofluorescence using an anti CENP-A antibody (green 
signals in c, red signals in d. FISH analysis using a D17Z1 probe (red 
in c, green in d identified FIXAC (arrowhead) and the endogenous 
 chromosome 17s.
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Five cell lines containing FIXACs in >90% of chromosome spreads 
were selected for further analysis (Table 1).
Mitotic stability and CENP-A deposition on FIXACs
The mitotic stability of FIXACs in HT1080 cells was examined in 
five cell lines (Figure 3a and Table 1). FIXACs were retained in 
70% of cells after 120 days of non-selective culture in lines TX9A2 
and TX9C2 (loss rate (R) = 0.003), indicating that FIXACs have 
assembled a functional centromere and are highly mitotically 
stable. In three further lines, FIXACs were detected in 75–100% 
of cells after 30 days culture in the absence of selection, corre-
sponding to loss rates of 0–0.0076 (Table 1). Consistent with the 
formation of a kinetochore, the centromere-specific histone H3 
variant centromere protein A (CENP-A)18 assembled on FIXACs 
(Figure 2c and d and Table 1). To rule out the possibility that 
FIXACs had achieved mitotic stability through acquisition of 
host α-satellite sequences, chromosome spreads were hybridized 
with an α-satellite consensus probe that had been preannealed 
with unlabeled D17Z1 sequences. No signal (above background) 
was detectable on FIXACs (Table 1; data not shown). This result, 
together with the complete overlap of D17Z1 and PACFIX hybrid-
ization signals with 4 ,6-diamidino-2-phenylindole fluorescence, 
suggests that FIXACs are de novo in composition and comprise 
input DNA sequences only.
Input BAC17:PACFIX ratio determines FIX transgene 
copy number on FIXACs
The FISH signal intensity with a PACFIX probe was markedly 
elevated compared to the endogenous X chromosome signal, 
on all FIXACs generated from the 2:1 or 1:1 input DNA ratios 
(Figure 2a). In contrast, the FISH signal intensity on FIXACs 
in 4 of 5 lines generated from a 20:1 input DNA ratio, was simi-
lar to the endogenous signal (Figure 2b). These observations 
suggested that the BAC17:PACFIX input ratio may determine 
FIX transgene copy number on FIXACs. To examine this pos-
sibility further, Southern analysis and semi-quantitative real 
time polymerase chain reaction (PCR) (qPCR) assays were 
performed. Genomic DNA was isolated from cell lines TX9A2 
and TX9C2.6 (generated from the 2:1 input ratio) and lines 
TX10B1 and TX10B7 (generated from the 20:1 input ratio). In 
each sample, the predicted 5.5 kb EcoRI fragment was detected 
by Southern analysis (Figure 3b). Additional weaker signals 
were also detected in lines TX9A2 and TX9C2.6, indicating a 
degree of input DNA rearrangement. In comparison to TX10B1 
and TX10B7, the 5.5 kb FIX signal was significantly elevated in 
TX9A2 and TX9C2.6, consistent with a higher transgene copy 
number per FIXAC in these lines. Based on the qPCR analy-
sis, FIXACs in lines TX9A2 and TX9C2.6 assembled an average 
of 14.9 and 25.1 FIX transgenes, respectively, whereas FIXACs 
in lines TX10B1 and TX10B7 assembled either no transgenes 
or an average 0.7 FIX genes/FIXAC, respectively (Figure 3d). 
These values are in close agreement with densitometric analy-
sis of the 5.5 kb FIX band detected by Southern hybridization 
(Figure 3b; data not shown). To assess FIX gene integrity, SfiI 
and NotI digested genomic DNA was examined by Southern 
analysis (Figure 3c). A strongly hybridizing band at 37 kb, 
derived from the PACFIX input DNA (Figure 1a), was detected 
in lines TX9A2 and TX9C2.6 indicating the presence of multiple 
intact FIX transgenes. In TX10B7, a band at 37 kb was detectable 
at lower intensity, consistent with the presence of an intact FIX 
transgene (see Supplementary Figure S1). The presence of addi-
tional bands indicated that rearranged FIX genes are also present 
in these three cell lines. In line TX10B1, FIX transgenes were not 
detected suggesting that only remnants of PACFIX excluding the 
FIX gene are present on the AC.
Low levels of FIX transcription from FIXACs 
assembling multiple FIX transgenes
FIX expression would not be predicted in the lung derived 
HT1080 cell line as FIX is limited in expression to hepatocytes. 
However, previous reports of transcription of the β-globin trans-
gene on a de novo human AC in HT1080 cells10 led us to exam-
ine FIX transcription from FIXAC. FIX transcripts were not 
detected from the endogenous HT1080 FIX locus, as expected, 
or in cell lines TX10B1 or TX10B7 harboring low FIX transgene 
(≤1) copy number FIXACs (Figure 4a and b). In contrast, FIX 
messenger RNA (mRNA) was detected at a level comparable to 
the human liver control in lines TX9A2 and TX9C2.6 (Figure 4b 
and c) that harbor multiple FIX transgenes. Northern analysis 
confirmed the presence of the predicted 2.8 kb FIX mRNA in 
both cell lines (Figure 4b). Structural integrity of FIX mRNA 
in and TX9A2 and TX9C2.6 was further confirmed by reverse 



















TX9A2 2:1 100 14.9 3.4 (2–11) 100 (0) + + Yes
TX9C2 2:1 100 (25) nd 2.9 (1–6) 100 (0) nd + nd
TX9C2.6 2:1 100 25 4.0 (2–5) 100 (0) + + Yes
TX10B1 20:1 95 (5) 0 2.0 (1–4) 95 (0) + - Yes
TX10B7 20:1 90 (25) 0.7 4.8 (1–10) 75 (0.0076) + - Yes
Abbreviations: nd, not done; RT-PCR, reverse transcriptase polymerase chain reaction.
aFIXAC is a human artificial chromosome (ACs) that has incorporated a 33 kb human Factor IX (FIX) gene(s) and chromosome 17 α-satellite DNA sequences. bThe molar 
ratio of BAC17:PACFIX DNA used in the transfection mixture is indicated. c% of chromosome spreads harboring FIXACs within each cell line is indicated. Numbers 
in parentheses indicate the % of spreads where a signal on a host chromosome was detected in addition to FIXAC. dAverage FIX transgene copy number/FIXAC was 
determined by semi-quantitative real-time PCR (Figure 3d). eMean FIXAC copy number/cell and range is indicated. f% spreads retaining FIXACs following 30 days 
culture without selection. Loss rate (R) was calculated as described in Figure 3. gKinetochore formation on FIXACs was evaluated using CENP-A antibody (Figure 2d 
and e). hRT-PCR and Northern analysis were used to determine whether FIX transcription from FIXAC was detectable (Figure 4). iFIXACs were considered de novo in 
composition if they did not hybridize to a pan-centromere probe in which D17Z1 sequences were competed out (data not shown). 
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transcriptase PCR (RT-PCR) using primers spanning the FIX 
complementary DNA (cDNA) which yielded a pattern compa-
rable to the liver control, with little or no evidence of aberrant 
FIX mRNA transcripts (Supplementary Figure S2).
Stable segregation of FIXAC in rodent cells
A prerequisite for development of a mouse model of AC mediated 
gene therapy is that FIXACs segregate stably in a rodent cell back-
ground. Using the procedure of microcell-mediated chromosome 
transfer, FIXACs were transferred from TX9C2.6 (Table 1) into 
LA9 (mouse fibroblast) and CHL (Chinese hamster lung) cells. In 
addition to providing a test of FIXAC segregation potential, LA9 
and CHL FIXAC monochromosomal hybrids will serve as effi-
cient microcell donors for subsequent FIXAC transfer into stem 
cells. Approximately 120 colonies were obtained following fusion 
of microcells prepared from the TX9C2.6 cell line and CHL cells. 
FISH analysis of 10 BSR CHL lines using a human Cot1 DNA probe 
that hybridizes to all human chromosomes, demonstrated that 9 of 
10 lines were monochromosomal hybrids that harbored FIXAC as 
the only human chromosome (data not shown). Three monochro-
mosomal hybrid lines (CHL10, CHL13, CHL15) in which FIXACs 
were detected in ≥95% of chromosome spreads without detectable 
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Figure 3 Factor IX artificial chromosome (FIXAC) mitotic stability 
and structural analysis. (a) Lines TX9A2 and TX9C2 were passaged 
for 120 days under non-selective conditions. FIXAC retention was ana-
lyzed at 30 day intervals using fluorescence in situ hybridization analy-
sis with PACFIX and D17Z1 probes. Loss rate (R) was calculated using 
the formula Nn = N0 × (1-R)
n, where N0 = percentage of metaphase 
spreads with FIXACs in cells cultured under selection, Nn = percent-
age of FIXAC-containing metaphase spreads after n days of culture in 
the absence of selection. (b) Genomic DNA was digested with EcoR1, 
blotted and hybridized with a FIX probe that recognizes a 5.5 kb frag-
ment (upper panel). A β-actin probe was used as a loading control 
(bottom panel). (c) Identification of intact FIX transgenes on FIXAC. 
High molecular weight DNA was digested with NotI and SfI1 to excise 
a 37 kb fragment (arrowhead) encompassing the 33 kb FIX locus that 
is specific to FIXAC (Figure 1a). In HT1080 cells, the endogenous sig-
nal at ~120 kb reflects the presence of two FIX genes in male HT1080 
cells that are close to tetraploid in chromosome composition. The posi-
tions of DNA size markers are indicated in kilobases (kb). (d) Real-time 
polymerase chain reaction (real-time PCR) analysis (qPCR) on genomic 
DNA was used to quantify FIX transgene copy number in each cell line. 
The number of FIX transgenes per FIXAC was determined by dividing 
the total number of FIX genes (corrected for the two endogenous FIX 

























































































Figure 4 Factor IX (FIX) transcription from FIXACs. (a) Reverse tran-
scriptase polymerase chain reaction (RT-PCR) was used to determine 
whether FIX messenger RNA (mRNA) is transcribed from FIXACs. FIX 
primers amplified a 780 bp product (FIX) in lines TX9A2 and TX9C2.6, as 
well as the human liver control. In lines TX10B1, TX10B7, and parental 
HT1080 cells, the FIX RT-PCR product was not detected. Control prim-
ers amplified a 498 bp hypoxanthine–guanine phosphoribosyltransfer-
ase (HPRT) product. (b) Northern analysis. The 2.8 kb FIX mRNA was 
detected in lines TX9A2 and TX9C2 and human liver, but not in lines 
TX10B1, TX10B7, or HT1080. The ethidium bromide stained 28S ribo-
somal subunit is shown as a loading control. (c) FIX mRNA quantitation 
using semi-quantitative real-time RT-PCR. Y axis is relative FIX mRNA levels 
in arbitrary units (AU). Samples were normalized to β-actin. In HT1080, 
TX10B1, and TX10B7, FIX mRNA was not detectable (data not shown). 
Error bars show mean + SD and are based on two replicates.
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examined (Figure 5a). The average FIXAC copy number per cell 
was 1.9, 1.1, and 3.4/cell in CHL10, CHL13 and CHL15, respec-
tively. In line CHL15, FIXACs exhibited a high level of mitotic sta-
bility and were retained in 90% of cells after 60 days growth without 
selection (R = 0.0018) (Figure 6a). FIXACs in lines CHL10 and 
CHL13 exhibited either a moderate (R = 0.0114) or high loss rate 
(R = 0.0503), respectively, demonstrating variation in the segrega-
tion efficiency of FIXAC in CHL cells. Four BSR LA9 colonies were 
obtained following microcell-mediated chromosome transfer. In 
3/4 lines, FIXACs were detected as a high copy number chromo-
some. Consistent with earlier studies,19,20 the high copy number 
FIXACs were mitotically unstable and not further studied (data 
not shown). In a fourth line, L1, FIXACs were detected in 90% of 
chromosome spreads at a low copy number (average 1.7/cell), and 
without detectable FIXAC translocations (Figure 5b). Although 
the mouse kinetochore protein, Cenp-c assembled on FIXAC in 
L1 cells (Figure 5c), FIXACs were retained in only 8% of cells 
following 30 days in non-selective conditions (R = 0.0744). This 
aggregate loss rate may reflect a uniformly high level of FIXAC 
instability or FIXAC stability may be heterogeneous such that 
a subpopulation of cells harbors a mitotically stable FIXAC. To 
investigate this latter possibility, L1 cells were plated at low density 
to generate single colonies that were expanded to form subclonal 
lines. Five subclonal L1 lines were identified in which FIXACs 
were present in 92–100% of chromosome spreads. Over 30 days 
passage without selection, FIXAC mitotic stability was higher than 
in the parent L1 line, with retention of FIXACs in 72–28% of cells 
(R = 0.0081−0.0402) (Figure 6b). This improved mitotic stability 
did not result from acquisition of minor satellite DNA (the func-
tional mouse centromeric sequence) as a minor satellite probe did 
not hybridize to FIXAC in L1 cells (Figure 5b) or in subclonal 
lines (data not shown). To rule out gross structural FIXAC insta-
bility, FIXAC structure was examined by Southern analysis using 
a chromosome 17 α-satellite probe (Figure 6c). The BAC17 con-
struct would produce a 99 kb ApaI fragment if no rearrangement 
of the input DNA had occurred. Fragments ranging from ~10 to 
194 kb were detected, confirming input DNA rearrangement dur-
ing chromosome formation (Figure 6c). Furthermore, an identi-
cal pattern of hybridization was obtained in all lanes suggesting 
that FIXACs are structurally stable. Confirmation that FIXACs 
comprise alternating DNA segments derived from the two input 
molecules was obtained by performing FISH on L1 extended 
DNA fibers (Figure 5d). Both LA9 and CHL cells tested negative 
for FIX expression with RT-PCR. However, consistent with the 
results in TX9C2.6, FIX transgene transcription persisted from 
FIXACs in rodent cells (Figure 6d and e). Interestingly, the level 
of FIX transcription was variable among the rodent cell lines and 
appeared unrelated to FIXAC mitotic stability.
DISCUSSION
The present study demonstrates that a 33 kb FIX gene can be assem-
bled efficiently into a de novo human AC (FIXAC) by co-transfec-
tion of two large DNA molecules (PACFIX and BAC17) of defined 
sequence. The 175 kb human genomic PAC (PACFIX) spans the 
FIX locus while the 99 kb centromeric BAC17 vector has 86.4 kb 
of synthetic α-satellite DNA. The AC formation rate was higher 
using co-transfection than using BAC17 as the sole input mole-
cule (Figure 1b). The increased AC formation rate may reflect the 
presence of additional replication origins, insulator elements for 
setting up chromatin domains or assembly of transcription factors 
as a result of incorporation of the FIX genomic segment. In com-
parison, co-transfection of a hypoxanthine–guanine phosphori-
bosyltransferase PAC and a chromosome 21 α-satellite PAC into 
HT1080 cells yielded a lower efficiency with only 5 of 25 cell lines 
forming an AC in 10–50% of spreads.5 While differences in vector 
and α-satellite sequence may contribute to these differences in AC 
formation rates, it has recently been shown that the genomic seg-
ment incorporated into a human AC can also significantly impact 
this process.10 We have demonstrated that the ~45 kb polycystic 
kidney disease 1 locus can be incorporated into ACs (using the 
co-transfection strategy) with efficiency similar to the FIX locus, 
and that input DNA ratio in the transfection mixture again influ-
enced transgene number on human ACs (A.M.B., R.L. Bacallao, 
B.R.G., unpublished results). Interestingly, integration frequencies 
were markedly lower in this instance. A better understanding of 
parameters affecting chromosome formation versus integration 
and increased control over input DNA rearrangements during 
chromosome formation will be required before de novo human 
ACs can be applied in a therapeutic setting.
In addition to providing correct spatial and temporal regu-
lation, an AC borne therapeutic transgene should be expressed 
at a physiologically appropriate level, making transgene copy 
number an important consideration. In the present study we 
demonstrate that the input ratio of BAC17:PACFIX determined 
FIX transgene copy number on FIXACs (Figure 3). When the 
BAC17 construct was introduced in 20-fold excess to PACFIX, 
FIXACs that assembled ≤1 FIX transgene were generated. In con-
trast, FIXACs generated from a 2:1 BAC17:PACFIX input ratio 
Figure 5 Factor IX artificial chromosome (FIXAC) transfer into rodent 
cell lines using microcell-mediated chromosome transfer (MMCT). 
The human HT1080 line TX9C2.6 formed microcells very efficiently and 
was used as a donor for transfer of FIXAC into rodent cells using MMCT. 
(a, b) PACFIX probe (green) hybridized with FIXAC (arrow) in Chinese 
hamster lung (CHL) monochromosomal hybrid CHL10 (a) and mouse LA9 
monochromosomal hybrid L1 (b). (b) Mouse minor satellite probe (red) 
is detected exclusively on the endogenous mouse centromeres. (c) The 
mouse centromere protein, Cenp-c, is detected on FIXAC in L1 cells as 
well as endogenous mouse centromeres. The PACFIX probe (green) con-
firmed FIXAC identity. Insets (a–c) show 4’,6-diamidino-2-phenylindole 
stained FIXACs. (d) Stretched DNA fibers from L1 cells hybridized with a 
D17Z1 probe (red) and PACFIX (green). The interspersed hybridization 
pattern suggests that FIXACs are composed of multiple copies of each 
input DNA molecule arranged as alternating segments.
© The American Society of Gene Therapy
FIX Gene Assembly on a Human Artificial Chromosome
320 www.moleculartherapy.org  vol. 16 no. 2 feb. 2008   
incorporated an average of 14.9 and 25.1 FIX transgenes in two 
independent lines. Furthermore, an association was observed 
between elevated transgene copy number and a low level of FIX 
misexpression in lung derived HT1080 cells (Figure 4) although 
previous studies indicated that sufficient regulatory sequences 
to direct liver specific expression should be contained within 
the PACFIX construct.17 FIX mRNA detection in lines harbor-
ing FIXACs with multiple transgenes could also indicate that 
transgenes are not completely silenced. In contrast, no transcrip-
tion was detected from the single FIX transgene in line TX10B7. 
Whilst this raises the possibility that copy number is critical to 
appropriate transgene regulation, inactivation of this transgene 
through minor rearrangement undetected by Southern analysis, 
cannot be excluded.
In transgenic mouse models, it has been demonstrated that 
genes introduced either as naked DNA or on human chromosomes 
or their derivatives, undergo chromatinization during the differ-
entiation process to result in the correct gene expression pattern 
(reviewed in refs. 21,22). An important question for their thera-
peutic application is whether an AC borne transgene introduced 
via an undifferentiated stem cell from a committed donor is appro-
priately remodeled. Pertinent data are currently sparse. Mouse 
studies will allow a comprehensive analysis of the regulation of the 
AC borne FIX gene and its capacity to provide phenotypic rescue 
of hemophilia B.
In order to develop a mouse model of AC mediated gene 
therapy it is necessary that the transgene bearing AC segregates 
stably in a rodent cell background. Human chromosomes esti-
mated to be less than 50 Mb in size, including de novo human 
ACs, segregated with a reduced efficiency in mouse LA9 cells 
compared to human cells in previous studies6,19,20,23 and two 
reports have implicated chromosome size as a factor in decreased 
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Figure 6 Factor IX artificial chromosome (FIXAC) mitotic stability and FIX transcription in Chinese hamster lung (CHL) and LA9 monochro-
mosomal hybrids. (a, b) CHL monochromosomal hybrid (MCH) cell lines CHL10, CHL13 and CHL15 (a) and LA9 MCH cell lines, L1 and L1 subclones 
(L1.2, L1.4, L1.6, L1.7 and L1.10) (b) were passaged in the absence of selection. FIXAC mitotic stability was measured using fluorescence in situ 
hybridization analysis at 30 and 60 days for CHL MCH lines (a) and at 30 days for LA9 MCH lines (b). PACFIX was used to detect FIXACs in CHL and 
LA9 MCHs. In LA9 lines, a mouse minor satellite probe was also used which hybridized only to mouse centromeres and not to FIXACs in L1 and L1 
subclones (Figure 5b; data not shown). (c) Structural integrity of FIXACs in L1 cells and L1 subclones was examined using Southern analysis of ApaI 
digested high molecular weight DNA. Digested DNA was separated on a pulsed field gel, blotted and hybridized with a chromosome 17 specific 
α-satellite probe, which hybridized exclusively to FIXACs. Positions of mid range DNA size markers in kb are indicated. (d, e) Reverse transcriptase 
polymerase chain reaction (RT-PCR) analysis of FIX mRNA transcription from FIXACs in L1, L1.7 (d) and CHL MCH lines (e). A 780 bp human FIX RT-
PCR product was amplified in L1, L1.7, CHL10, CHL13, and CHL15 complementary DNA (cDNA), as well as in human liver control cDNA. Reactions 
with mouse Hprt (mHprt, 286 bp product) or human HPRT (498 bp product) primers were included as controls in d. Primers spanning either Chinese 
hamster Hprt (cHprt) or human HPRT (hHPRT) were used as controls in e.
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segregation competence.15,20 FIXAC assembled the mouse kineto-
chore protein, Cenp-c, upon transfer into LA9 cells but exhibited 
a high initial missegregation rate. However, FIXACs exhibited 
higher mitotic stability in subclonal lines suggesting an improved 
segregation competence of a subset of FIXACs (Figure 6b). 
Similar results were obtained with a 7–10 Mb sized human mini 
X chromosome in LA9 cells.20 Since Southern analysis indicated 
that FIXACs maintain structural stability (Figure 6c) and FISH 
analysis demonstrated that the mouse centromere sequence is 
absent from FIXACs (Figure 5b; data not shown), the improved 
segregation efficiency in subclonal lines probably reflects more 
effective maintenance of centromeric chromatin and kinetochore 
proteins on FIXACs. Local epigenetic modifications of chroma-
tin are thought to be important for building a foundation for 
the kinetochore and for maintenance of centromeric cohesion 
(reviewed in refs. 24,25). We are currently investigating whether 
chromatin composition differs between mitotically stable and 
unstable FIXACs in LA9 cells as this may influence their segre-
gation potential. In hamster cell lines, FIXAC segregated with 
variable efficiencies. In one line (CHL15), the FIXAC segrega-
tion efficiency matched that of the human donor (Figures 6a and 
3a). It is likely that epigenetic effects also influence FIXAC seg-
regation potential in hamster cells. The generation of rodent cell 
lines, which efficiently segregate FIXACs, suggests that FIXACs 
will function in transgenic animal models. The feasibility of ani-
mal studies is further supported by the stable segregation in mice 
of de novo human ACs harboring either the GCH1 gene or the 
globin gene cluster.7 The demonstration that FIXAC can be stably 
maintained in vivo without deleterious effect and provide sus-
tained phenotypic rescue would constitute significant progress 
towards clinical applications.
AC based gene therapy will ultimately depend on a suitable 
means of AC delivery to target tissues with cultured stem or pro-
genitor cells being the most promising vehicle. The stable segre-
gation of truncated human and mouse chromosomal vectors in 
human mesenchymal cells, CD34+ hematopoietic stem cells and 
bone marrow-derived mononuclear cells, supports the possibility 
that de novo human ACs could be delivered by this route (reviewed 
in refs. 22,26–29). Rapid advance in the area of stem cell biology 
combined with ongoing vector refinement make the goal of AC 
based gene therapy appear increasingly attainable.
MATERIALS AND METHODS
BAC and PAC constructs. BAC17 is VJ104-17α32, and has been described 
in detail (Figure 1a).13 PACFIX is clone RP6-88D7 and was purchased 
from Children’s Hospital Oakland Research Institute (Oakland, CA) and 
has a sequenced 158557 bp human genomic DNA insert (National Center 
for Biotechnology Information accession number AL033403) from Xq25-
26.3 cloned into the pPAC4 vector.30 The PACFIX insert includes the 33 kb 
human FIX gene, 4077 bp upstream sequence and 121780 bp of down-
stream sequence. A 3  truncated copy of the MCF2 gene is also present on 
the PACFIX insert.
Cell culture. HT1080 cells were grown in α-minimum essential medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum 
(Hyclone, Logan, UT). Mouse LA9 cells were grown in RPMI 1640 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. 
CHL cells were grown in Dulbecco’s modified Eagle’s medium/F12 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum.
Transfection of BAC and PAC constructs into human HT1080 cells. 
Human ACs were generated in the HT1080 (human fibrosarcoma) cell 
line. BAC17 and PACFIX constructs were co-transfected into HT1080 
cells using either a 1:1, 2:1 or 20:1 BAC17:PACFIX molar ratio. As a con-
trol, BAC17 was independently transfected into HT1080 cells to generate 
BAC17-based ACs. In each transfection, 1–2 μg of DNA was introduced 
using Lipofectamine Reagent (Invitrogen, Carlsbad, CA). G418 selection 
(300 μg/ml) (Mediatech, Herndon, VA) was applied at 48 hours post-
transfection. Colonies appeared after 10–14 days and were individually 
expanded to generate cell lines.
FISH and immunofluorescence. Metaphase chromosomes were prepared 
from G418R or BSR cell lines and analyzed using FISH to permit detec-
tion of human ACs using standard procedures. Cell lines generated from 
co-transfection of BAC17 and PACFIX constructs were hybridized with a 
chromosome 17 α-satellite (D17Z1) probe, p17H831, and PACFIX. Control 
cell lines generated from transfection of BAC17 were hybridized with the 
BAC vector (VJ104)13 and p17H8 (Figure 1b). Probes were labeled directly 
with either spectrum red or spectrum green labeled deoxyuridine tri-
phosphate using a commercial kit (Vysis, Downers Grove, IL). The prim-
ers used to amplify the consensus α-satellite probe have been described.32 
Ten micrograms of p17H8 were used to compete D17Z1 sequences in the 
consensus α-satellite probe (Table 1). The mouse minor satellite probe 
(Figure 5b) was generated by PCR using mouse LA9 genomic DNA as 
a template with the minor satellite primers (5 TATCCATGAGTTAC 
AATG3 ), (5 CATTGTAACTCATTGATA3 ). ≥20 metaphases were scored 
in each sample. Extended DNA fibers (Figure 5d) were prepared as before33 
and hybridized with PACFIX and p17H8 probes. Kinetochore formation 
on FIXACs was determined by indirect immunofluorescence using a 
human CENP-A antibody (gift from Manuel Valdivia34 or purchased from 
AbCam, Cambridge, MA) or an anti mouse Cenp-c antibody35 (gift from 
Andy Choo) on unfixed, cytospun chromosomes according to published 
methods.36 A fluorescein isothiocyanate–conjugated secondary antibody 
(Jackson ImmunoResearch, West Grove, PA) was used to detect CENP-A 
(Figure 2e and f) or Cenp-c (Figure 5c). Following CENP-A or Cenp-c 
detection, slides were hybridized with p17H8 (Figure 2e and f) or PACFIX 
(Figure 5c) probes to permit FIXAC identification. Pseudo-colored images 
were captured using a Leica DM5000B fluorescence microscope equipped 
with a Spot RTKE camera (Diagnostic Instruments, Sterling Heights, MI) 
and processed using Adobe Photoshop.
Mitotic stability. Lines harboring FIXACs were analyzed using FISH anal-
ysis of ≥20 chromosome spreads to determine FIXAC mitotic stability fol-
lowing 30–120 days of growth under non-selective conditions. In human 
and CHL lines, probes were PACFIX and p17H8. In L1 cells and sub-clonal 
lines, probes were PACFIX and minor satellite.
Microcell mediated chromosome transfer. FIXAC was transferred into 
rodent cells using a microcell-mediated chromosome transfer and was 
carried out as previously described with minor modifications.37 Details of 
this method are provided as supplementary information (Supplementary 
Figure S3). FIXAC transfer into rodent cells was confirmed using FISH 
analysis with PACFIX and p17H8 probes. A human CotI probe (Invitrogen, 
Carlsbad, CA) was used to confirm that only FIXAC was transferred into 
recipient lines.
FIX mRNA detection by RT-PCR. Total RNA was extracted from cell lines 
using TRIzol Reagent (Invitrogen, Carlsbad, CA). cDNA was generated 
from 5 μg of total RNA using SuperScript First-Strand Synthesis (Invitrogen, 
Carlsbad, CA). Human liver RNA was purchased from Clontech (Mountain 
View, CA). Primers were as follows: human FIX (5 -ATGACTTCACTCG 
GGTTGTTG3 ), (5 -GTGAGAGGCCCTGTTAATTTTC-3 ) (Figures 4a 
and 6d and e); human hypoxanthine–guanine phosphoribosyltransferase 
(5 -CTTCCTCCTCCTGAGCAGTC-3 ), (5 -CCTGACCAAGGAAAGC 
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AAAG-3 ) (Figures 4a and 6d and e); mouse hypoxanthine–guanine phos-
phoribosyltransferase (5 -TTGCTGACCTGCTGGATTAC-3 ), (5 -CGAG 
 AGGTCCTTTTCACCAG-3 ) (Figure 6d); Chinese hamster hypoxan-
thine–guanine phosphoribosyltransferase (5 - GATCCATTCCCATGA 
CTGTAG-3 ), (5 -ATCCAACACTTCGAGAGGTC-3 ) (Figure 6e). RT-
PCR conditions for human and mouse cDNA were 94 °C for 2 minutes; 
94 °C for 45 seconds, 58 °C for 1 minute, 72 °C for 45 seconds (35 cycles); 
72 °C for 5 minutes. For hamster cDNA, RT-PCR conditions were 94 °C for 
2 minutes; 94 °C for 45 seconds, 63.9 °C for 1 minute, 72 °C for 45 seconds 
(35 cycles); 72 °C for 5 minutes. In control RT-PCR reactions set up with 
each primer pair but with no cDNA added, RT-PCR products were not 
amplified (data not shown). Primers were intron spanning and did not 
amplify a product in genomic DNA (data not shown).
Northern and Southern analyses. For Northern analysis (Figure 4b), 
5 μg of total RNA was loaded in each lane, electrophoresed and blot-
ted onto Hybond N+ membrane (GE Healthcare, Piscataway, NJ) using 
standard conditions. For conventional Southern analysis (Figure 3b), 
each lane was loaded with 10 μg of EcoRI digested genomic DNA. High 
molecular weight DNA (Figures 3c and 6c) was prepared by embedding 
1.7 × 107 cells/ml (Figure 3c) or 1.7 × 106 cells/ml (Figure 6c) in agarose 
plugs,13 and digested either with SfiI and NotI (Figure 3d) or ApaI (Figure 
6c) then separated using pulsed field gel electrophoresis on a BioRad Chef 
II mapper for 15 hours at 14 °C in 0.5 × Tris/borate/EDTA with an initial 
switch time of 0.2 seconds, final switch time of 13.0 seconds and voltage 
set at 6V/cm. DNA was transferred onto Hybond N+ membrane. Filters 
were hybridized with deoxycytidine triphosphate–α-32P labeled probes. 
Southern and Northern blots were hybridized in 7% sodium dodecyl sul-
fate, 0.5 mol/l NaPO4 (Figures 3b and c and 4b). The Southern blot in 
Figure 6c was hybridized in 7% sodium dodecyl sulfate, 0.5 mol/l NaPO4, 
20% formamide. Final wash for Southern blots was 65 °C in 75 mmol/l 
sodium chloride/7.5 mmol/l sodium citrate/0.5% sodium dodecyl sul-
fate. Final wash for the Northern blot (Figure 4b) was 65°C in 15 mmol/l 
sodium chloride/1.5 mmol/l sodium citrate/0.5% sodium dodecyl sulfate. 
The FIX probe used in Figure 4b was a 1.4 kb FIX cDNA excised from plas-
mid PND912 (gift from Elliot Rosen, Indiana University). The FIX probe 
used in Figure 3b and c was a 699 bp fragment generated by PCR from 
human cDNA using the primers (5 -ATGCATTCTGTGGAGGCTCT-3 ), 
(5 -GTGAGAGGCCCTGTTAATTTTC-3 ). The β-actin probe (Figure 3b) 
was amplified from human genomic DNA using the following primer 
pair: (5 -CTATCCCTGTACGCCTCTGG-3 ), (5 -GAAGGAAGGCTGG 
AAGAGTG-3 ). Primers used to amplify a 0.8 kb chromosome 17 spe-
cific α-satellite probe (Figure 6c) are published.38 Filters were exposed to 
a phosphorimager screen (GE Healthcare, Piscataway, NJ) and scanned 
using a Storm Optical Scanner (Molecular Dynamics, Sunnyvale, CA).
Real-time PCR. Semi-quantitative real-time PCR reactions were carried 
out in a 25 μl volume using SYBR GREEN PCR Master Mix (Applied 
Biosystems, Warrington, UK) on an Applied Biosystems 7500 Real-
Time PCR machine. Relative quantitation was performed using the 
standard curve method (Figures 3d and 4c). FIX gene copy numbers in 
genomic DNA (Figure 3c) were determined using the following prim-
ers: (5 -GTGAGAGGCCCTGTTAATTTTC-3 ), (5 -AAGGTATCCCGG 
TATGTCAAC-3 ). Genomic β-actin primers (Figure 3c) were (5 -CTA 
TCCCTGTACGCCTCTGG-3 ), (5 -TGGTGGTGAAGCTGTAGCC-3 ). 
To amplify FIX message from human cDNA (Figure 4c), intron spanning 
primers (5 -ATGCCAAAC CAGGTCAATTC-3 ), (5 -ATGTTCACCTGC 
GACAACTG-3 ) were used. Human β-actin control primers (Figure 4c) 
were also intron spanning: (5 -TTCTACAATGAGCTGCGTGTG-3 ), 
(5 -GTACATGGCTGGGGTGTTG-3 ).
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SUPPLEMENTARY MATERIAL
Figure S1. Detection of a FIX transgene in line TX10B7. 
Figure S2. Detection of RT-PCR products spanning the 2.8 kb FIX 
mRNA. 
Figure S3. Detailed method for microcell-mediated chromosome 
transfer of FIXACs into rodent cells.
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